###begin article-title 0
###xml 78 83 <span type="species:ncbi:9606">Human</span>
###xml 117 121 <span type="species:ncbi:10090">Mice</span>
Immunoglobulin-Like Transcript 3-Fc Suppresses T-Cell Responses to Allogeneic Human Islet Transplants in hu-NOD/SCID Mice
###end article-title 0
###begin p 1
###xml 45 62 45 62 <email xmlns:xlink="http://www.w3.org/1999/xlink">ns20@columbia.edu</email>
Corresponding author: Dr. Nicole Suciu-Foca, ns20@columbia.edu
###end p 1
###begin p 2
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See  for details.
###end p 2
###begin p 3
###xml 0 10 0 10 <bold xmlns:xlink="http://www.w3.org/1999/xlink">OBJECTIVE&#8212;</bold>
OBJECTIVE-The aim of our study was to explore the immunomodulatory activity of soluble immunoglobulin (Ig)-like transcript (ILT) 3-Fc in pancreatic islet transplantation and to determine its mechanism of action.
###end p 3
###begin p 4
###xml 0 28 0 28 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESEARCH DESIGN AND METHODS&#8212;</bold>
###xml 37 41 <span type="species:ncbi:10090">mice</span>
###xml 123 128 <span type="species:ncbi:9606">human</span>
###xml 153 157 <span type="species:ncbi:10090">Mice</span>
###xml 304 309 <span type="species:ncbi:9606">human</span>
###xml 540 545 <span type="species:ncbi:9606">human</span>
RESEARCH DESIGN AND METHODS-NOD/SCID mice in which diabetes was induced by streptozotocin injection were transplanted with human pancreatic islet cells. Mice in which the transplant restored euglycemia were humanized with allogeneic peripheral blood mononuclear cells and treated with ILT3-Fc or control human IgG or left untreated. The blood glucose level was monitored twice a week, and rejection was diagnosed after two consecutive readings >350 mg/dl. Tolerated and rejected grafts were studied histologically and by immunostaining for human T-cells and insulin production. CD4 and CD8 T-cells from the spleen were studied for suppressor activity, expression of cytokines, and CD40L.
###end p 4
###begin p 5
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESULTS&#8212;</bold>
###xml 215 216 215 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 339 340 339 340 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 17 22 <span type="species:ncbi:9606">human</span>
###xml 85 89 <span type="species:ncbi:10090">mice</span>
###xml 175 179 <span type="species:ncbi:10090">mice</span>
###xml 330 335 <span type="species:ncbi:9606">human</span>
###xml 528 533 <span type="species:ncbi:9606">human</span>
###xml 616 621 <span type="species:ncbi:9606">human</span>
###xml 671 675 <span type="species:ncbi:10090">mice</span>
RESULTS-Although human T-cell engraftment was similar in all groups, ILT3-Fc-treated mice tolerated the islets for the entire period of observation (91 days), whereas control mice rejected the graft within 7 weeks (P < 0.0001). ILT3-Fc treatment suppressed the expression of cytokines and CD40L and induced the differentiation of human CD8+ T suppressor cells that inhibited Th alloreactivity against graft HLA antigens. T-cells allostimulated in vitro in the presence of ILT3-Fc inhibited CD40L-induced upregulation of CD40 in human pancreatic islet cells. Histochemical studies showed dramatic differences between human pancreatic islets from tolerant, ILT3-Fc-treated mice and control recipients rejecting the grafts.
###end p 5
###begin p 6
###xml 0 12 0 12 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CONCLUSIONS&#8212;</bold>
###xml 143 147 <span type="species:ncbi:10090">mice</span>
CONCLUSIONS-The data indicated that ILT3-Fc is a potent immunoregulatory agent that suppressed islet allograft rejection in humanized NOD/SCID mice.
###end p 6
###begin p 7
Published ahead of print at  on 16 April 2008.
###end p 7
###begin p 8
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
###end p 8
###begin p 9
###xml 258 259 258 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 260 261 260 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 671 672 671 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 673 675 673 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 886 887 886 887 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 945 946 945 946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
###xml 947 949 947 949 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
Transplantation of isolated pancreatic islets is a promising approach to curative therapy of type 1 diabetes. However, many immunosuppressive drugs, including corticosteroids, cyclosporin, and tacrolimus, are either diabetagenic or toxic to the islet cells (1-3). The development of nondiabetagenic regimens that induce immunological tolerance without the hardship of chronic immunosuppressive therapy remains a major goal in islet transplantation. Experimental data suggest that prolonged islet allograft survival can be achieved using biological modifiers, such as monoclonal antibodies and soluble receptor ligands, which block T-cell activation and/or costimulation (4-13). Such attempts include the blockade of the CD40-CD40L costimulatory pathway deemed to be crucial to the activation and differentiation of T effector cells. Because CD40 is expressed by pancreatic islet cells (8), blockade of this pathway may be particularly relevant (6-12).
###end p 9
###begin p 10
###xml 70 71 70 71 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 189 190 189 190 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 246 247 246 247 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 353 354 353 354 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 358 359 358 359 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 668 670 664 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 671 673 667 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 61 66 <span type="species:ncbi:9606">human</span>
###xml 237 242 <span type="species:ncbi:9606">human</span>
In previous studies, we have shown that alloantigen-specific human CD8+ T suppressor (Ts) cells can be generated both in vitro and in vivo by chronic antigenic stimulation. We generated CD8+ Ts cells by multiple in vitro stimulations of human CD3+ T-cells with allogeneic, xenogenic, or allopeptide-pulsed autologous antigen-presenting cells (APCs). CD8+CD28- Ts cells from such cultures interacted with priming APCs in an antigen-specific, major histocompatibility complex class I-restricted and contact-dependent manner, inducing the upregulation of the Ig-like transcript (ILT) 3 and ILT4 and inhibiting nuclear factor-kappaB activation and CD40 signaling in APCs (14-18).
###end p 10
###begin p 11
###xml 274 276 274 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r19">19</xref>
###xml 277 279 277 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r21">21</xref>
###xml 450 451 450 451 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 545 546 537 538 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 577 579 569 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r22">22</xref>
###xml 688 689 680 681 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 848 850 840 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r23">23</xref>
###xml 981 982 973 974 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 993 995 985 987 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r24">24</xref>
###xml 784 788 <span type="species:ncbi:10090">mice</span>
###xml 823 828 <span type="species:ncbi:9606">human</span>
###xml 864 867 <span type="species:ncbi:10116">rat</span>
ILT3 and ILT4 have extracellular Ig-like domains responsible for ligand binding at the cell surface and a long cytoplasmic tail containing immunoreceptor tyrosine-based inhibitory motif, which recruits inhibitory phosphatases and transduces a negative signal into the cell (19-21). The crucial role of ILT3 in the induction of T-cell unresponsiveness was documented in experiments showing that ILT3-overexpressing dendritic cells induce anergy in CD4+ T helper cells and suppress the differentiation of interferon-gamma (IFN-gamma)-producing CD8+ cytotoxic T-lymphocyte (CTL) (22). Furthermore, membrane-bound and soluble ILT3 (rILT3-Fc fusion protein) elicited the differentiation of CD8+ Ts cells in primary 7-day mixed lymphocyte culture (MLC) and in vivo in humanized C.B-17 SCID mice, inducing tolerance to allogeneic human tumor transplants (23). Also, in a rat model of heart transplantation, we demonstrated that tolerance can be induced, maintained, and transferred by CD8+ Ts cells (24).
###end p 11
###begin p 12
###xml 67 72 <span type="species:ncbi:9606">human</span>
###xml 116 120 <span type="species:ncbi:10090">mice</span>
###xml 152 157 <span type="species:ncbi:9606">human</span>
###xml 214 218 <span type="species:ncbi:10090">mice</span>
Here, we report that treatment with ILT3-Fc prevented rejection of human pancreatic islets transplanted in NOD/SCID mice, which were reconstituted with human peripheral blood mononuclear cells (PBMCs) (hu-NOD/SCID mice).
###end p 12
###begin title 13
RESEARCH DESIGN AND METHODS
###end title 13
###begin p 14
###xml 16 20 <span type="species:ncbi:10090">mice</span>
NOD/SCID female mice purchased from Charles River Laboratories were used at 6-10 weeks of age. All protocols involving animal care procedures were approved by the Columbia University Institutional Animal Care and Use Committee. The animals were kept in microisolator cages and were fed autoclaved food and water. Diabetes was induced by intravenous injection of streptozotocin (STZ) (Sigma-Aldrich) at the dose of 180 mg/kg. Blood glucose level was measured twice a week using Ascensia Elite XL Blood Glucose Meter system (Bayer AG). Diabetes was diagnosed after two consecutive glucose measurements >350 mg/dl.
###end p 14
###begin title 15
###xml 65 69 <span type="species:ncbi:10090">mice</span>
Generation, transplantation, and treatment of humanized NOD/SCID mice.
###end title 15
###begin p 16
###xml 192 194 192 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r25">25</xref>
###xml 365 367 365 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r26">26</xref>
###xml 368 370 368 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r27">27</xref>
###xml 688 689 688 689 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 1048 1050 1047 1049 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r23">23</xref>
###xml 1348 1349 1347 1348 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 36 41 <span type="species:ncbi:9606">human</span>
###xml 151 155 <span type="species:ncbi:10090">mice</span>
###xml 373 377 <span type="species:ncbi:10090">Mice</span>
###xml 567 571 <span type="species:ncbi:10090">mice</span>
###xml 814 818 <span type="species:ncbi:10090">mice</span>
###xml 909 914 <span type="species:ncbi:9606">human</span>
###xml 1093 1097 <span type="species:ncbi:10090">mice</span>
###xml 1206 1211 <span type="species:ncbi:9606">human</span>
###xml 1338 1343 <span type="species:ncbi:9606">human</span>
###xml 1562 1567 <span type="species:ncbi:9606">human</span>
###xml 1595 1599 <span type="species:ncbi:10090">mice</span>
###xml 1621 1626 <span type="species:ncbi:9606">human</span>
###xml 1669 1674 <span type="species:ncbi:9606">human</span>
###xml 1738 1742 <span type="species:ncbi:10090">mice</span>
###xml 1847 1851 <span type="species:ncbi:10090">mice</span>
Aliquots of 1,500 islet equivalents human pancreatic islets with >70% purity and >90% viability were transplanted under the kidney capsule of NOD/SCID mice rendered diabetic by STZ injection (25). The viability of islets was determined by fluorescein diacetate and propidium iodine staining. Purity was determined by the percentage of dithizone-positive particles (26,27). Mice that did not restore to euglycemia after transplantation were eliminated from the study on the assumption that the grafted islets were not functional. Seven to 10 days posttransplantation, mice that were restored to euglycemia (glucose level <100 mg/dl) were "humanized" by intraperitoneal injection of 50 x 106 PBMCs, isolated from fresh buffy coats purchased from the New York Blood Center. Concomitant with the humanizing treatment, mice received the first of a series of 10 consecutive intraperitoneal injections of ILT3-Fc or human IgG from Sigma (250 mug/day) and were assigned to the ILT3-Fc treatment or IgG control group, respectively, as described previously (23). An additional control group of NOD/SCID mice was humanized and transplanted as above but received no treatment. Ten days after humanization, circulating human T-cells were evaluated by flow cytometry using heparinized retro-orbital venous samples. Animals failing to reconstitute (<5% human CD45+ PBMCs in the circulation) or developing graft-versus-host disease (hunched back, lethargy, weight loss, and tachypnea) were excluded from analysis by design. To avoid variability between samples, both islets and human PMBCs were administered to mice from the ILT3-Fc and human IgG group in a pairwise fashion. To study human T-cell engraftment and suppressor function, a second cohort of mice administered STZ was humanized, transplanted, and treated with IgG or ILT3-Fc as described above. These mice were killed at the onset or completion of allograft rejection in the control IgG-treated group.
###end p 16
###begin title 17
ILT3-Fc protein.
###end title 17
###begin p 18
###xml 64 66 64 66 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r22">22</xref>
ILT3-Fc protein expressed and purified as previously described (22) was analyzed by gel electrophoresis and mass spectrometry (MS). Matrix-assisted laser desorption ionization and liquid chromatography-MS/MS analysis of tryptic digests showed no contaminants.
###end p 18
###begin title 19
HLA typing.
###end title 19
###begin p 20
###xml 17 22 <span type="species:ncbi:9606">human</span>
HLA genotypes of human PBMCs and pancreatic islets were determined by PCR with sequence-specific primers using commercially available kits from One Lambda (Los Angeles, CA).
###end p 20
###begin title 21
Histology and immunochemistry.
###end title 21
###begin p 22
###xml 528 529 527 528 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
Twenty serial paraffin sections of kidney were cut at 4-mum thickness. Levels 1, 10, and 20 were stained for light microscopic evaluation (hematoxylin-eosin). The remaining sections were used for immunostains including insulin, CD4 (Biogenics, San Ramon, CA), CD3 and CD8 (Dako, Carpinteria, CA), and CD40 (Abcam, Cambridge, MA). Islet quantity and islet inflammatory infiltration (insulitis) were graded semiquantitatively in blinded fashion by a renal pathologist on a scale of 0 to 3+. The degree of islet inflammation by CD8+ T-cells was graded according to the number of CD8 per x40 high-power field: 0 (none), 1+ (1-10), 2+ (11-25), and 3+ (>25). The results were averaged over at least five high-power fields per slide.
###end p 22
###begin title 23
Ts cell assays.
###end title 23
###begin p 24
###xml 209 210 209 210 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 238 239 238 239 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 272 273 272 273 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 277 278 277 278 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 418 419 418 419 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 459 461 459 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r23">23</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 75 79 <span type="species:ncbi:10090">mice</span>
Human CD4 and CD8 T-cells were isolated from spleens of humanized NOD/SCID mice using the CD4 or CD8 isolation kits (StemCell Technologies). Sorted CD4 or CD8 T-cells were added at increasing numbers (1-8 x 104/well) to a fixed number (104/well) of unprimed autologous CD3+CD25- T-cells and stimulated for 6 days in MLC with irradiated, allogeneic PBMCs sharing HLA-A, -B, and -DR antigens with the islet transplant. [3H]thymidine incorporation was measured (23).
###end p 24
###begin title 25
Tissue culture for CD40L induction of CD40 upregulation in islet cells.
###end title 25
###begin p 26
###xml 177 178 176 177 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 226 227 225 226 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 351 352 350 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1</italic>
###xml 359 360 358 359 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 373 375 372 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 378 379 377 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 413 414 412 413 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 428 429 427 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">3</italic>
###xml 459 460 458 459 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 610 611 605 606 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 635 636 626 627 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 681 682 669 670 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 744 745 732 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 911 916 <span type="species:ncbi:10090">mouse</span>
Responding T-cells were allostimulated with irradiated PBMCs matching the HLA classes I and II of selected islet cultures in the presence of 50 mug/ml ILT3-Fc. After 7 days, CD8+ T-cells were isolated and tested. Nonprimed CD8+ T-cells from the same responder served as controls. Pancreatic islets selected as targets were co-incubated overnight with 1) CD40L+ D1.1 cells (18), 2) D1.1 cells plus allospecific CD8+ Ts cells, or 3) D1.1 cells plus unprimed CD8+ T-cells. Islets cultured alone were used to measure the constitutive level of CD40 expression, and islets cultured in tumor necrosis factor-alpha (106 units/l), IFN-gamma (106 units/l), and interleukin (IL)-1beta (5 x 104 units/l) were used as a positive control for CD40 induction (8). After 18 h, cells were washed, and the T-cells were depleted by incubation with anti-CD3 and anti-CD8 antibodies (Becton Dickinson, San Jose, CA) followed by anti-mouse magnetic beads (Invitrogen, Carlsbad, CA). Remaining cells were used for PCR and flow- cytometry studies.
###end p 26
###begin title 27
Real-time PCR.
###end title 27
###begin p 28
###xml 487 495 487 491 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;&#916;Ct</sup>
Total RNA was isolated with the RNAqueous-4PCR kit (Stratagene, La Jolla, CA). Complementary cDNA was synthesized using the 1st Strand cDNA Synthesis Kit for RT-PCR (Roche Diagnostics, Basel, Switzerland). Real-time PCR was performed using proprietary Taqman gene expression primer probes (Applied Biosystems, Foster City, CA). Data were collected and analyzed with the 7300 SDS 1.3.1 software (Applied Biosystems). The relative amount of gene expression was calculated by the formula: 2-DeltaCt, where DeltaCt = [Ct(gene) - Ct(glyceraldehyde-3-phosphate dehydrogenase)] and Ct is the "crossing threshold" value returned by the PCR instrument for every gene amplification.
###end p 28
###begin title 29
Fluorescence-activated cell sorting analysis.
###end title 29
###begin p 30
###xml 140 142 140 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r23">23</xref>
Flow-cytometry studies were performed on a FACSCalibur instrument using six-parameter acquisition (BD Biosciences) as previously described (23).
###end p 30
###begin title 31
Statistical analysis.
###end title 31
###begin p 32
###xml 139 140 139 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
Graft survival curves were computed using the Kaplan-Meir method. Differences between groups were compared by the log-rank test. Student's t test was used to analyze differences in cytokine and cell surface marker expression. The BMDP statistical software package was used for all analyses.
###end p 32
###begin title 33
RESULTS
###end title 33
###begin title 34
Immunomodulatory effect of ILT3-Fc.
###end title 34
###begin p 35
###xml 464 466 464 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r23">23</xref>
###xml 9 13 <span type="species:ncbi:10090">mice</span>
###xml 63 68 <span type="species:ncbi:9606">human</span>
###xml 264 269 <span type="species:ncbi:9606">human</span>
NOD/SCID mice with STZ-induced diabetes were transplanted with human islets under the kidney capsule. When they became euglycemic, they were injected intraperitoneally with freshly isolated PBMCs from healthy blood donors and assigned to control groups (receiving human IgG or no treatment) or to the treatment group, which received a daily intraperitoneal injection of ILT3-Fc over a period of 10 days starting the day of PBMC injection, as previously described (23).
###end p 35
###begin p 36
###xml 33 34 33 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 61 62 61 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 234 235 234 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 286 292 286 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1</xref>
###xml 386 387 386 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 228 232 <span type="species:ncbi:10090">mice</span>
Mice from the group not treated (n = 6) or treated with IgG (n = 8) rejected the graft within 3 to 7 weeks as demonstrated by soaring glucose levels and by histology studies. In contrast, none of the ILT3-Fc-treated hu-NOD/SCID mice (n = 8) became diabetic over 91 days of observation (Fig. 1), indicating that ILT3-Fc inhibited rejection of islet allografts in hu-NOD/SCID recipients (P = 0.0001).
###end p 36
###begin title 37
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 40 44 <span type="species:ncbi:10090">mice</span>
Human T-cell engraftment in Hu-NOD/SCID mice.
###end title 37
###begin p 38
###xml 10 11 10 11 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 178 179 178 179 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 293 294 291 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 330 331 326 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 384 385 378 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 41 45 <span type="species:ncbi:10090">mice</span>
###xml 169 174 <span type="species:ncbi:9606">human</span>
###xml 287 291 <span type="species:ncbi:10090">mice</span>
###xml 324 328 <span type="species:ncbi:10090">mice</span>
###xml 355 359 <span type="species:ncbi:10090">mice</span>
###xml 373 378 <span type="species:ncbi:9606">human</span>
Human CD45+ PBMC engraftment in NOD/SCID mice recipients of allogeneic islet transplants was analyzed by flow cytometry. Ten days after PBMC injection, the frequency of human CD3+ T-cells in the peripheral blood of hu-NOD/SCID islet allograft recipients was 11 +/- 3% in ILT3-Fc-treated mice (n = 8), 10 +/- 2% in untreated mice (n = 6), and 10 +/- 4% in mice treated with human IgG (n = 8).
###end p 38
###begin p 39
###xml 430 431 426 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 664 665 658 659 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 679 680 673 674 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 710 711 704 705 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 110 115 <span type="species:ncbi:9606">human</span>
###xml 167 171 <span type="species:ncbi:10090">mice</span>
###xml 560 565 <span type="species:ncbi:9606">human</span>
To determine whether the outcome of the pancreatic islet transplant was influenced by the number of engrafted human T-cells, we analyzed their frequency in spleens of mice killed at the time of rejection or at the termination of the study (day 91). In untreated or IgG-treated animals, the frequency ranged from 24 to 59% (mean 41 +/- 16) and from 25 to 62% (mean 45 +/- 16), respectively. In euglycemic animals killed on day 91 (n = 8), the frequency ranged from 28 to 71% (mean 50 +/- 22). The difference between the groups was not significant. Less than 1% human T-cells was found in the bone marrow of ILT3-Fc-treated or control animals. No engraftment of CD19+ B-cells, CD56+ natural killer cells, or CD14+ monocytes were found in the spleens and bone marrow of these animals. These data indicate that the outcome of the graft was determined not by the number but, rather, by the functional state of chimeric T-cells in animals treated versus those not treated with ILT3-Fc.
###end p 39
###begin title 40
Generation of regulatory T-cells in ILT3-Fc-treated animals.
###end title 40
###begin p 41
###xml 146 147 146 147 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 158 160 158 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r23">23</xref>
###xml 50 54 <span type="species:ncbi:10090">mice</span>
###xml 195 200 <span type="species:ncbi:9606">human</span>
###xml 243 247 <span type="species:ncbi:10090">mice</span>
###xml 359 363 <span type="species:ncbi:10090">mice</span>
In previous studies, we demonstrated that hu-SCID mice that have been rendered tolerant to allogeneic tumors by treatment with ILT3-Fc develop CD8+ Ts cells (23). To determine whether regulatory human T-cells also differentiate in hu-NOD/SCID mice, we tested in parallel the suppressive activity of CD8 and CD4 T-cells magnetically sorted from the spleens of mice that received the pancreatic islets and PBMCs from the same allogeneic donors.
###end p 41
###begin p 42
###xml 43 47 <span type="species:ncbi:10090">mice</span>
###xml 221 225 <span type="species:ncbi:10090">mice</span>
###xml 365 370 <span type="species:ncbi:9606">human</span>
###xml 438 443 <span type="species:ncbi:10090">mouse</span>
###xml 516 521 <span type="species:ncbi:10090">mouse</span>
###xml 608 613 <span type="species:ncbi:10090">mouse</span>
###xml 650 655 <span type="species:ncbi:10090">mouse</span>
For these studies, we used two hu-NOD/SCID mice treated with ILT3-Fc and two IgG-treated controls, which were not included in the computation of actuarial graft and host survival because they were killed by design. These mice were transplanted with pancreatic islets from a donor expressing HLA-A1, -B8, -DR3/A2, -B44, and -DR7. One pair was killed on day 23 after human PBMC injection, when the glycemia was 240 mg/dl in the IgG-treated mouse, suggesting the onset of rejection, and 72 mg/dl in the ILT3-Fc-treated mouse. The second pair was killed on day 47 with a glycemia of 380 mg/dl in the IgG-treated mouse and 80 mg/dl in the ILT3-Fc-treated mouse.
###end p 42
###begin p 43
###xml 9 10 9 10 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 18 19 18 19 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human CD8+ and CD4+ T-cells magnetically sorted from the recipients' spleens were added in increasing numbers to MLC containing unprimed autologous T-cells, used as responders, and irradiated allogeneic (stimulating) PBMCs from an individual who was HLA matched to the islet cell donor.
###end p 43
###begin p 44
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 221 222 221 222 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 311 317 311 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2</xref>
###xml 47 51 <span type="species:ncbi:10090">mice</span>
CD8+ T-cells obtained from the ILT3-Fc-treated mice killed on days 23 and 47 suppressed T-cell reactivity in primary MLC by 67 and 78%, respectively, at an 8:1 ratio of regulatory to responding T-cells. At this ratio, CD4+ T-cells from these animals inhibited the MLC response by only 20 and 21%, respectively (Fig. 2).
###end p 44
###begin p 45
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 12 13 12 13 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 100 106 100 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2</xref>
###xml 432 433 432 433 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 550 551 550 551 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 640 641 640 641 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 649 650 649 650 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 879 885 879 885 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2</xref>
###xml 896 897 896 897 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 945 946 945 946 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1063 1064 1061 1062 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1223 1224 1221 1222 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 124 129 <span type="species:ncbi:9606">human</span>
###xml 194 199 <span type="species:ncbi:9606">human</span>
###xml 212 216 <span type="species:ncbi:10090">mice</span>
###xml 279 283 <span type="species:ncbi:10090">mice</span>
###xml 706 710 <span type="species:ncbi:10090">mice</span>
###xml 887 892 <span type="species:ncbi:9606">human</span>
###xml 911 915 <span type="species:ncbi:10090">mice</span>
CD8+ and CD4+ T-cells from IgG-treated animals killed at the same time had no suppressive activity (Fig. 2). Engraftment of human T-cells into recipients' spleens was similar in the ILT3-Fc-and human IgG-treated mice. These results were reproduced in an additional four pairs of mice killed 4 weeks (days 21 and 26) or 7 weeks (days 43 and 46) after transplantation. The data indicate that ILT3-Fc induced the differentiation of CD8+ Ts cells in hu-NOD/SCID recipients of allogeneic islet transplants. To further determine whether the presence of CD8+ Ts cells is associated with tolerance to the allogeneic islet transplants, we tested CD8+ and CD4+ T-cells from the spleens of ILT3-Fc-treated euglycemic mice killed on day 91. APCs sharing HLA antigens with the graft were used for stimulating T-cells autologous to the cells tested for suppressive activity. As illustrated in Fig. 2, human CD8+ T-cells from mice with long-lasting tolerance (n = 8) displayed suppressive activity, inhibiting the MLC response to donor HLA antigens by >70% (mean 85 +/- 10). CD4+ T-cells from the same animals showed weak inhibitory activity (<20%). The data indicate that ILT3-Fc treatment prevents islet allograft rejection inducing CD8+ regulatory T-cells.
###end p 45
###begin title 46
###xml 30 35 <span type="species:ncbi:9606">human</span>
Characterization of engrafted human T-cells.
###end title 46
###begin p 47
###xml 358 359 354 355 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 367 368 363 364 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 450 451 446 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 444 451 440 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>A</italic></xref>
###xml 91 95 <span type="species:ncbi:10090">mice</span>
###xml 120 125 <span type="species:ncbi:9606">human</span>
###xml 182 187 <span type="species:ncbi:9606">human</span>
###xml 248 252 <span type="species:ncbi:10090">mice</span>
To further characterize the phenotype and function of effector and suppressor T-cells from mice rejecting or tolerating human islet allografts, we performed real-time PCR studies on human CD4 and CD8 T-cells sorted from the spleens of six pairs of mice killed during weeks 4 and 7 after humanization. The expression of IFN-gamma, IL-2, IL-5, and IL-10 by CD4+ and CD8+ T-cells was significantly lower in ILT3-Fc-than in IgG-treated recipients (Fig. 3A).
###end p 47
###begin p 48
###xml 39 40 39 40 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 44 45 44 45 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 97 98 97 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 130 131 130 131 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 136 137 136 137 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 163 164 163 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 265 266 265 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 259 266 259 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>B</italic></xref>
###xml 287 288 287 288 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 433 434 433 434 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 487 489 487 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 490 492 490 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r16">16</xref>
By flow cytometry, the frequency of CD8+CD28- T-cells was significantly higher on weeks 4 and 7 (P = 0.011 and 0.048), whereas CD8+CD40L+ was significantly lower (P = 0.007 and 0.022) in ILT3-Fc-treated animals compared with paired controls as illustrated in Fig. 3B. This profile of CD8+ T-cells from animals treated with ILT3-Fc that have developed Ts cells is consistent with our previous findings on the CD28-low phenotype of CD8+ Ts cells that act in a cytokine-independent manner (14-16).
###end p 48
###begin title 49
Modulation of CD40L-induced upregulation of CD40 in islet cells.
###end title 49
###begin p 50
###xml 135 136 131 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 204 205 200 201 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 568 569 563 564 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 635 636 630 631 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 697 698 692 693 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 816 818 811 813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r22">22</xref>
###xml 819 821 814 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r23">23</xref>
###xml 843 844 838 839 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1485 1491 1480 1486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4</xref>
###xml 1506 1507 1501 1502 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1625 1626 1620 1621 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1702 1707 <span type="species:ncbi:9606">human</span>
Because pancreatic islet cells express a functional CD40 receptor and signaling through this receptor activates nuclear factor-kappaB (8), we studied the possibility that allospecific, ILT3-Fc-induced CD8+ Ts cells are able to modulate the expression of CD40 in islet cells. For this purpose, T-cells from healthy blood donors were stimulated for 7 days in MLC with irradiated allogeneic APCs matching the HLA genotype of pancreatic islet cell cultures from three different individuals. ILT3-Fc (50 mug/ml) was added to the medium at the initiation of the culture. CD8+ T-cells primed in the presence of ILT3-Fc differentiated into CD8+ Ts cells, which inhibited the MLC response of autologous CD4+ T-cells and induced the upregulation of ILT3 on priming APCs in a pattern consistent with that described previously (22,23). ILT3-Fc-induced CD8+ Ts cells were then added to the corresponding islet cell culture together with CD40L-transfected D1.1 cells at a ratio of 1:1:1. Islets co-incubated with D1.1 alone or with D1.1 cells plus unprimed CD8 T-cells and islets stimulated with the cytokine mixture or left unstimulated were tested in parallel. Real-time PCR analysis showed that the cytokine mixture induced maximal upregulation of CD40 expression. D1.1 cells also induced the transcriptional upregulation of the CD40 costimulatory molecule in pancreatic islets. In three independent experiments, allospecific Ts cells inhibited to baseline levels D1.1-induced CD40 upregulation (Fig. 4). Unprimed CD8+ T-cells had no effect on CD40 triggering by CD40L-expressing D1.1 cells. These results indicate that allospecific CD8+ Ts cells generated in vitro suppress CD40L-induced upregulation of CD40 in human pancreatic islet cells.
###end p 50
###begin title 51
Histology.
###end title 51
###begin p 52
###xml 206 207 206 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 208 209 208 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 200 209 200 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>A</italic>&#8211;<italic>D</italic></xref>
###xml 238 239 238 239 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 313 314 313 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 319 320 319 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 307 320 307 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>D</italic> and <italic>C</italic></xref>
###xml 480 481 480 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 486 487 486 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 474 487 474 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>F</italic> and <italic>E</italic></xref>
###xml 55 60 <span type="species:ncbi:9606">human</span>
###xml 168 173 <span type="species:ncbi:9606">human</span>
###xml 255 260 <span type="species:ncbi:9606">human</span>
###xml 286 291 <span type="species:ncbi:10090">mouse</span>
###xml 395 399 <span type="species:ncbi:10090">mice</span>
Comparison of islet-transplanted kidneys 23 days after human PBMC administration showed that the quantity of islets was greater in the ILT3-Fc-treated (3+) than in the human IgG-treated (2+) animals (Fig. 5A-D). There was insulitis by CD8+ T-cells in the human IgG-but not ILT3-treated mouse (2+ vs. 0.5+) (Fig. 5D and C). Immunostaining for CD40 showed diffuse membrane staining in IgG-treated mice and rare focal membrane staining in islets from the ILT3-Fc-treated pair (Fig. 5F and E).
###end p 52
###begin p 53
###xml 125 126 125 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 131 132 131 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 119 132 119 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>A</italic> and <italic>B</italic></xref>
###xml 151 152 151 152 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 241 242 241 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 247 248 247 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 235 248 235 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>C</italic> and <italic>D</italic></xref>
###xml 449 450 449 450 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 113 117 <span type="species:ncbi:10090">mice</span>
###xml 229 233 <span type="species:ncbi:10090">mice</span>
###xml 451 456 <span type="species:ncbi:9606">human</span>
Pairwise comparison on day 47 showed that islet quantity was greater in treated (mean 3+) than control (mean 1+) mice (Fig. 6A and B). Insulitis by CD8+ T-cells was markedly reduced in treated (mean 0.5+) vs. control (mean 2.5+) mice (Fig. 6C and D). By light microscopy, islets with insulitis from control animals exhibited scattered apoptotic bodies. By immunostains in both groups, the lymphocytes infiltrating and surrounding the islets were CD8+ human T-cells.
###end p 53
###begin p 54
###xml 184 185 181 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 190 191 187 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 178 191 175 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f7" ref-type="fig">Fig. 7<italic>B</italic> and <italic>D</italic></xref>
###xml 275 276 272 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 281 282 278 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 269 282 266 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f7" ref-type="fig">Fig. 7<italic>A</italic> and <italic>C</italic></xref>
###xml 442 443 439 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 436 443 433 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f7" ref-type="fig">Fig. 7<italic>E</italic></xref>
###xml 558 559 555 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 552 559 549 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f7" ref-type="fig">Fig. 7<italic>F</italic></xref>
###xml 141 146 <span type="species:ncbi:10090">mouse</span>
###xml 465 469 <span type="species:ncbi:10090">mice</span>
Pairwise comparison of insulin immunostains on day 47 showed markedly reduced expression of insulin on islet beta-cells from the IgG-treated mouse, indicating impaired function (Fig. 7B and D), compared with strong and diffuse expression in the ILT3-Fc-treated animal (Fig. 7A and C). At 3 months, the tolerated islets displayed strong and diffuse staining for insulin, indicating that they were functionally active and well tolerated (Fig. 7E). In ILT3-Fc-treated mice killed on day 91, there was a large quantity of islets (3+) and no insulitis (0) (Fig. 7F), consistent with the notion that the graft was well tolerated. Taken together, these findings indicate that ILT3-Fc treatment inhibits the onset and progression of islet allograft rejection.
###end p 54
###begin title 55
DISCUSSION
###end title 55
###begin p 56
###xml 580 582 580 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r25">25</xref>
###xml 583 585 583 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r28">28</xref>
###xml 586 588 586 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r36">36</xref>
###xml 63 69 <span type="species:ncbi:9606">humans</span>
###xml 369 373 <span type="species:ncbi:10090">mice</span>
###xml 402 406 <span type="species:ncbi:10090">mice</span>
###xml 422 427 <span type="species:ncbi:9606">human</span>
###xml 556 561 <span type="species:ncbi:9606">human</span>
Although many biological mechanisms are similar in rodents and humans, there are several structural and functional differences that render the extrapolation of experimental results to clinical practice quite difficult. Multiple transgenic, knockout, and reconstituted models of autoimmune diseases have been developed over the past 2 decades. The creation of humanized mice, defined as immunodeficient mice engrafted with human hematopoietic stem cells or PBMCs, provided a powerful tool for preclinical testing of new immunomodulatory agents and study of human immune responses (25,28-36). This is particularly true in the case of ILT3, which, like other members of the Ig gene superfamily, has no ortholog in rodents.
###end p 56
###begin p 57
###xml 120 122 120 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r31">31</xref>
###xml 123 125 123 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r34">34</xref>
###xml 175 177 175 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r34">34</xref>
###xml 285 287 285 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r25">25</xref>
###xml 288 290 288 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r28">28</xref>
###xml 291 293 291 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r35">35</xref>
###xml 294 296 294 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r36">36</xref>
###xml 433 435 433 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r34">34</xref>
###xml 859 860 859 860 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 914 915 914 915 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1098 1099 1098 1099 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1213 1215 1213 1215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 1216 1218 1216 1218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r22">22</xref>
###xml 1219 1221 1219 1221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r23">23</xref>
###xml 1616 1618 1612 1614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r37">37</xref>
###xml 50 54 <span type="species:ncbi:10090">mice</span>
###xml 145 150 <span type="species:ncbi:9606">human</span>
###xml 210 215 <span type="species:ncbi:9606">human</span>
###xml 427 431 <span type="species:ncbi:10090">mice</span>
###xml 673 678 <span type="species:ncbi:9606">human</span>
###xml 905 910 <span type="species:ncbi:9606">human</span>
In addition to T- and B-cell deficiency, NOD/SCID mice have functional defects of macrophages and natural killer cells (31-34) and high rates of human lymphocyte engraftment (34), providing a tool for studying human islet allograft rejection and the effect of immunomodulatory agents (25,28,35,36). The rate of T-cell engraftment observed in our study was similar to that described by other authors studying the same strain of mice (34). Using ILT3-Fc treatment, we prevented rejection of pancreatic islet transplants in 100% of hu-NOD/SCID recipients over a 91-day observation period. To our knowledge, this is the highest rate of successful transplantation of allogeneic human islets in a preclinical model in which the efficacy of a biological agent was tested alone without any pharmaceutical immunosuppression. Tolerance to the islets was mediated by CD8+ Ts cells as demonstrated by the capacity of human CD8+ T-cells, sorted from the spleen of ILT3-Fc-treated hu-NOD/SCID islet recipients, to inhibit the response of autologous T-cells to donor HLA antigens in primary MLC. Most of these CD8+ Ts cells displayed a CD28-low phenotype reminiscent of Ts cells generated in vitro by multiple allostimulations (14,22,23). Treatment with ILT3-Fc inhibited the capacity of both CD4 and CD8 T-cells to produce Th1-type (IFN-gamma and IL-2) and Th2-type (IL-5 and IL-10) cytokines. Inhibition of Th2-type cytokines is important in islet transplantation because alloantibodies against donor HLA antigens and autoantibodies against the pancreas compromise not only graft survival but also chances for retransplantation (37).
###end p 57
###begin p 58
###xml 22 23 22 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 232 233 232 233 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 379 380 379 380 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 698 700 698 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 701 703 701 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r38">38</xref>
###xml 729 730 729 730 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 985 986 985 986 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 223 228 <span type="species:ncbi:9606">human</span>
###xml 1079 1083 <span type="species:ncbi:10090">mice</span>
Because only a few CD8+ T-cells were found within the islet graft in ILT3-Fc-treated animals, the way in which they mediate tolerance to the graft is not quite clear. It is obvious, however, that direct interaction between human CD8+ T-cells and graft HLA class I antigens is required for priming and takes place within the graft. We postulate that in the absence of ILT3-Fc, CD8+ T-cells differentiate into effector CTLs, which proliferate within the graft, produce cytokines, induce inflammation, and promote the destruction of the islets. Because they express CD40L, a positively enhancing immunostimulant, they may provide the alarm signal that attracts other T-cells to the site of rejection (14,38). In contrast, primed CD8+ T-cells from ILT3-Fc-treated animals differentiate into Ts cells, which do not proliferate within the graft, produce no inflammatory cytokines, have low CD40L expression, and may thus be unable to trigger danger signals from the graft. The absence of CD8+ T-cell infiltrates and inflammatory changes of the graft supports this possibility. Because mice were humanized only after the graft was healed, trauma-related danger signals were unlikely to occur.
###end p 58
###begin p 59
###xml 224 225 221 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
###xml 226 227 223 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 228 230 225 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r10">10</xref>
###xml 231 233 228 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
###xml 234 236 231 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r39">39</xref>
###xml 237 239 234 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r40">40</xref>
There is evidence that the constitutive and selective expression of CD40 on the surface of beta-cells contributes to autoimmunity and islet allograft rejection by providing costimulatory signals to infiltrating lymphocytes (6,8,10,12,39,40).
###end p 59
###begin p 60
###xml 414 415 414 415 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 503 505 503 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r16">16</xref>
###xml 506 508 506 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r41">41</xref>
###xml 822 823 819 820 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 827 828 824 825 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1084 1086 1081 1083 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 97 105 <span type="species:ncbi:9606">patients</span>
###xml 531 539 <span type="species:ncbi:9606">patients</span>
It is, therefore, possible that in addition to suppressing islet allograft rejection in diabetic patients, ILT3-Fc may also prevent recurrence of diabetes by inhibiting the CD40-CD40L interaction between pancreatic islet cells and autoaggressive T-cells, primed to diabetagenic islet cell peptides presented by self-APCs. This possibility is strongly supported by our previous studies showing that allospecific CD8+ Ts cells inhibit CD40 signaling in APCs and T-cell reactivity to immunogenic peptides (16,41). Because in diabetic patients, selective autoimmune destruction of pancreatic beta-cells occurs alone or in combination with rejection of the transplanted islets, the discovery of agents that may block both of these pathological processes would be of paramount importance. Based on our previous findings that CD8+CD28- Ts cells are present in the circulation of successfully transplanted heart, liver, and kidney recipients and display the capacity to inhibit CD40L-CD40 interaction, we believe that induction of Ts cells by ILT3-Fc treatment may achieve this goal (rev. in 14).
###end p 60
###begin p 61
###xml 270 272 270 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r23">23</xref>
###xml 456 458 456 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r22">22</xref>
###xml 118 123 <span type="species:ncbi:9606">human</span>
###xml 189 194 <span type="species:ncbi:9606">human</span>
###xml 248 256 <span type="species:ncbi:9606">patients</span>
Taken together, our data demonstrate for the first time that ILT3-Fc is a potent immunoregulatory agent that inhibits human islet allograft rejection. Because sILT3 is a natural product of human APCs, found to be elevated and to induce Ts cells in patients with cancer (23), this biological agent is unlikely to be toxic or have undesirable side effects. Furthermore, because the ligand for ILT3 is expressed only by activated and not by unprimed T-cells (22), this agent is not expected to cripple the immune system by depleting or blocking naive T-cells. Further research will be necessary to fully assess the potential usefulness of ILT3-Fc for treatment of diabetes and suppression of islet allograft rejection.
###end p 61
###begin p 62
###xml 466 471 <span type="species:ncbi:9606">Human</span>
This work was supported by a grant from the Juvenile Diabetes Research Foundation (JDRF 5-2006-957) and by the Interuniversitary Organ Transplantation Consortium (Rome, Italy). Islets were received from the Islet Cell Resource Consortium (administered by the Administrative and Bioinformatics Coordinating Center and supported by the National Center for Research Resources, the National Institute of Diabetes and Digestive and Kidney Diseases, and the JDRF) and the Human Islet Isolation and Distribution Program at Washington University School of Medicine, supported by JDRF 6-2006-1099.
###end p 62
###begin title 63
REFERENCES
###end title 63
###begin p 64
###xml 241 242 241 242 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 335 336 334 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 371 372 370 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 441 442 414 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 68 72 <span type="species:ncbi:10090">mice</span>
###xml 92 96 <span type="species:ncbi:10090">mice</span>
###xml 145 150 <span type="species:ncbi:9606">human</span>
###xml 159 163 <span type="species:ncbi:10090">Mice</span>
###xml 254 259 <span type="species:ncbi:9606">human</span>
###xml 346 351 <span type="species:ncbi:9606">human</span>
ILT3-Fc treatment prevents islet allograft rejection in hu-NOD/SCID mice. Diabetic NOD/SCID mice were transplanted under the kidney capsule with human islets. Mice in which euglycemia was restored were injected intraperitoneally with 50 x 106 allogeneic human PBMCs and treated for 10 days with 250 mug/day of ILT3-Fc (treatment group n = 8, o), human IgG (control group n = 8, blacksquare, square, filled), or left untreated (control group n = 6, *). Glycemia levels >350 mg/dl were considered indicative of rejection-induced diabetes.
###end p 64
###begin p 65
###xml 319 320 283 284 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 412 413 376 377 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 52 57 <span type="species:ncbi:9606">human</span>
###xml 112 116 <span type="species:ncbi:10090">mice</span>
###xml 155 159 <span type="species:ncbi:10090">Mice</span>
###xml 196 201 <span type="species:ncbi:9606">Human</span>
###xml 265 269 <span type="species:ncbi:10090">mice</span>
Ts cell assays in ILT3-Fc-treated (triangle up) and human IgG-treated (blacksquare, square, filled) hu-NOD/SCID mice recipients of allogeneic islet cells. Mice were killed on days 23, 47, and 91. Human CD4 and CD8 T-cells were isolated from the spleen of recipient mice and added to MLC containing naive, autologous CD3+ T-cells and irradiated allogeneic PBMC HLA matched to the islet donor. Tritiated thymidine[3H], incorporation was measured after 6 days.
###end p 65
###begin p 66
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 63 64 63 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 72 73 72 73 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 245 246 214 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 259 260 228 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 412 413 381 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 54 59 <span type="species:ncbi:9606">human</span>
###xml 152 157 <span type="species:ncbi:9606">human</span>
###xml 337 341 <span type="species:ncbi:10090">mice</span>
###xml 471 476 <span type="species:ncbi:9606">human</span>
A: Real-time PCR studies of cytokine transcription by human CD4+ and CD8+ T-cells from the spleens of ILT3-Fc-treated (blacksquare, square, filled) and human IgG-treated (square) hu-NOD/SCID recipients of islet allografts killed during weeks 4 (n = 3) and 7 (n = 3) posttransplantation. For clarity, the data generated from each pair of mice were normalized to unity in the control group; mean and SE are shown. B: Flow-cytometry analysis of CD28 and CD40L expression on human CD8 T-cells colonizing the spleens of ILT3-Fc-and IgG-treated pairs of animals killed during weeks 4 and 7 posttransplantation. One pair representative of three is shown for each time point.
###end p 66
###begin p 67
###xml 231 232 231 232 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 274 275 274 275 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 45 50 <span type="species:ncbi:9606">human</span>
###xml 75 80 <span type="species:ncbi:9606">Human</span>
Real-time PCR analysis of CD40 expression in human pancreatic islet cells. Human pancreatic islet cells were cultured alone or with a mixture of inflammatory cytokines, CD40L-transfected D1.1 cells, D1.1 cells plus allospecific CD8+ Ts cells, or D1.1 cells plus unprimed CD8+ T-cells. After 18 h of incubation, T-cells were depleted, and the remaining islets were analyzed by real-time PCR for expression of CD40. The values are expressed as means +/- SD.
###end p 67
###begin p 68
###xml 21 22 21 22 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 32 33 32 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 34 35 34 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 47 48 47 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 53 54 53 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 105 106 105 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 108 109 108 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 115 116 115 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 135 136 135 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 138 139 138 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 145 146 145 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 157 161 <span type="species:ncbi:10090">mice</span>
Immunostaining of CD8+ T-cells (A-D) and CD40 (E and F) in islet-engrafted kidneys from ILT3-Fc-treated (A, C, and E) and IgG-treated (B, D, and F) NOD/SCID mice 23 days after humanization.
###end p 68
###begin p 69
###xml 90 91 90 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 96 97 96 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 122 123 122 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 128 129 128 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 103 108 <span type="species:ncbi:9606">human</span>
###xml 140 145 <span type="species:ncbi:10090">mouse</span>
Hematoxylin-eosin and CD8 immunostaining of islet-engrafted kidneys from ILT3-Fc-treated (A and C) and human IgG-treated (B and D) NOD/SCID mouse 47 days after humanization.
###end p 69
###begin p 70
###xml 86 87 86 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 92 93 92 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 112 113 112 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 118 119 118 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 183 184 183 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 218 219 218 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 130 134 <span type="species:ncbi:10090">mice</span>
Immunostaining of insulin expression in islet-engrafted kidneys from ILT3-Fc-treated (A and C) and IgG-treated (B and D) NOD/SCID mice 47 days after humanization. Insulin expression (E) and hematoxylin-eosin staining (F) in tolerated islets on day 91.
###end p 70

